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After the identification of the Epstein-Barr virus, 2 BL became a model for the exploration of chromosomal aberrations in cancer. From their cytogenetic analyses of BL cell lines, Kohn et al. 3 observed abnormalities of C-group chromosomes. In 1972, Manolov and Manolova 4 reported a marker band at the end of chromosome 14. Zech et al. 5 were the first to suggest that a translocation event occurred between the telomeric end of the long arm of chromosome 14 and the telomeric end of the long arm of chromosome 8. Variant translocations towards 2p and 22q were described in BL cell lines in 1979. 6, 7 The molecular targets of these translocations were discovered to be MYC (at 8q24), 8, 9 and genes coding for the immunoglobulin heavy chain (IGH at 14q32), 10 kappa light chain (IGK at 2p12) 11 and lambda light chain (IGL at 22q11). 12 All translocations juxtapose the MYC gene to one of the IG enhancers, which results in constitutive deregulation of MYC expression. Although it is considered to be the hallmark of BL, translocation of MYC is not specific, as it is also seen in other types of lymphomas. 13 
Current diagnostic dilemma
Although a correct diagnosis of classic BL can easily be made using a combination of clinical, histological, immunophenotypical and genetic criteria including the presence of a translocation involving MYC, 14 problems arise when considering other B-cell Non-Hodgkin's lymphomas (B-NHL) with one or more overlapping features with BL. Especially the distinction between BL and a small subset of diffuse large B-cell lymphoma (DLBCL) with multiple characteristics of BL (for example, morphological features, a MYC translocation and/or a very high proliferation index) appears to be problematic. 15 This distinction has important clinical implications for treatment and prognosis, as BL responds relatively poor to standard DLBCL therapy (CHOP-like regimen) but excellent to high-intensity chemotherapy. [16] [17] [18] As this distinction may be difficult using the current diagnostic tools, 19 several groups have focused on new parameters. [19] [20] [21] [22] [23] [24] Recently, two comprehensive gene-expression studies on the subject have been published, showing some differences in outcome. In both studies, BL could be distinguished from other aggressive lymphomas by a distinctive gene expression pattern, that is, the combination of expression levels of multiple genes being able to predict a diagnosis of BL (predictor or index). Cases with a high index were called 'molecular BL' and cases with a low index 'non-molecular BL.' According to the Molecular Mechanisms in Malignant Lymphomas (MMML) Network Project study, 25 the greater majority of mature aggressive B-cell lymphomas cases could be classified as either molecular BL or DLBCL, but an intermediate zone remained, as 48 of 219 (22%) of the cases could not be classified, as molecular BL or non-molecular BL. Moreover, 81% of all conventionally classified BL but also 11 of 165 (7%) morphologic DLBCL had a molecular profile of BL (Table 1a) . No real intermediate group existed in the study of the Lymphoma/Leukemia Molecular Profiling Project (LLMPP); 26 however, 7 out of 20 (35%) morphologically difficult to classify DLBCL cases had a molecular profile of BL (Table 1b) . Furthermore, in the MMML study bcl-2 expression and BCL2 translocations were observed in 9 and 1 out of the 44 molecular BL cases, respectively. 25 From the 53 molecular BL cases of the LLMPP study, 5 cases showed bcl2 protein expression and 3 had a BCL2 breakpoint in addition to the MYC breakpoint. 26 Both observations are in contrast with the criteria of the WHO classification from 2001.
14 These contradictions point to the possible utilization of additional criteria for a diagnostic definition of these intermediate lymphomas.
Role of genetics in the diagnosis of BL
Another approach to distinguish 'true' BL cases from mimickers might be the inclusion of genomic criteria in addition to the MYC-translocation. In 1982, Berger et al. 27 reported that approximately 40% of the BL/leukemia cases have a t (8;14) or variant translocation as the sole cytogenetic abnormality. The lack of complex genetic alterations in addition to a MYC translocation might therefore be suggestive for a 'true' BL. 28, 29 The presence of an additional translocation as found in other types of B-NHL (for example, involving BCL2, BCL6 and/or CCND1) or a complex karyotype with multiple gains and/or losses would rather represent another type of B-NHL or a secondary transformed lymphoma. 30 This is supported by the publication of the MMML where array based comparative genomic hybridization (arrayCGH) was used to study genomic copy number imbalances in addition to fluorescent in situ hybridization (FISH) analysis for MYC, BCL2 and BCL6 translocations. In contrast to molecular BL, non-molecular BL were characterized by a less frequent IG-MYC translocation and by more additional genomic aberrations. 'Intermediate' cases were enriched for non-IG-MYC fusions, IG-MYC fusions in complex karyotypes and additional translocations of either BCL2 or BCL6. 25 A recent study of the LLMPP using CGH on BL revealed that the 'discrepant cases' (that is, molecular BL, but with aberrant morphology and/or immunophenotype) showed a more complex genetic make-up, including BCL2 breakpoints as detected by FISH. 31 These observations indicate that other genomic features than the MYC translocation status are important to distinguish 'true' BL from mimickers. The aim of this review is to define the cytogenetic profile of 'true' BL and to use this profile to distinguish BL from other B-cell lymphomas with an 8q24/MYC breakpoint.
The Mitelman database as a comprehensive cytogenetic resource
To base our analyses on the largest available set of lymphomas we chose the 'Mitelman Database of Chromosome Aberrations in Cancer' 32 as our resource. The edition of the Mitelman database (September 2007) contained 6359 B-cell malignancies. Overall, 865 B-NHL with an 8q24 translocation were selected, including 538 BL. In addition, 108 cases of morphologic BL without a documented 8q24 translocation became part of the data set. Mature 'Burkitt' leukemias (ALL-L3 according to the FAB classification) were included, but not lymphomas and leukemias derived from precursor B-cells and plasma cell-related disorders.
Although we included series published between 1976 5 and 2007 33 and we realized that immunohistochemistry and FISH became gradually available after 1976, we relied on the diagnostic assignment of the cases as given through the database. We therefore defined a core subset of BL using a minimal set of criteria applied throughout the entire period. These criteria are (a) morphologic diagnosis of BL, (b) presence of a translocation between chromosome bands 8q24 (suggestive for the MYC locus) and 2p12, 14q32 or 22q11 (suggestive for involvement of one of the IG loci) and (c) no (additional) breakpoint at 18q21, 3q27 or 11q13 (expected targets are BCL2, BCL6 and CCND1, respectively). This core subset was extensively analyzed, and compared with other B-NHL with an 8q24 translocation as well as cases of morphologic BL that did not fulfill all these criteria.
All karyotyping data were converted to an 862 band-specific status map, with breakpoint and imbalance information, using karyotype parsing software developed as part of the Progenetix project (www.progenetix.net; 34 supplementary information). Statistical differences between genomic profiles of individual groups were determined with the CGHMultiArray software (http://webmath.tue.nl/mark/cgh/index.html) at a P-value o0.05. 35 The differences between groups were calculated with the Fisher's exact test for nominal values and the student's t-test for continuous variables. Although we are aware that the mentioned cytogenetic aberrations might involve other molecular targets, for readability purposes we have used molecular terms instead of cytogenetic terms for the following cytobands: MYC for 8q24, BCL2 for 18q21, BCL6 for 3q27, CCND1 for 11q13, IGH for 14q32, IGK for 2p12 and IGL for 22q11.
Case selection and subgroup definition
The data set included 865 B-NHL with a MYC translocation ( Figure 1) ; 538 represented BL/leukemia and 327 cases another type of B-NHL (Supplementary Table 1 ). From the 538 BL cases, 525 (98%) had a translocation of MYC towards an IG locus (IG-MYC), the remaining 13 BL (2%) harbored a translocation of MYC towards a non-IG locus (non-IG-MYC). Out of the 327 other B-NHL with a MYC translocation, 256 (78%) harbored an IG-MYC translocation, while 71 cases (22%) harbored a non-IG-MYC translocation (significance of difference with BL Po0.0001). In addition, 108 morphologic BL cases without a confirmed MYC translocation were included.
In addition to the MYC translocation, 621 completely annotated translocation events were found in 380 cases. The most common translocations involved 18q21 (BCL2, N ¼ 126), 11q13 (CCND1, N ¼ 35) and 3q27 (BCL6, N ¼ 31), which are commonly seen in other types of lymphoma (for example, follicular lymphoma, mantle cell lymphoma and DLBCL). All cases with one or more of these translocations in addition to a MYC translocation were regarded as 'double-hit' (DH) lymphomas (N ¼ 177). In line with the new WHO classification of 2008, we used the expression DH throughout this manuscript and defined this as any kind of 8q24/MYC translocation plus any translocation involving 18q21/BCL2, 11q13/CCND1 or 3q27/ BCL6. Nevertheless, we realize that the expression 'double-hit' is not uniformly used by authors and moreover might not fully cover the heterogeneity of this group. It might even be more appropriate to use the expression 'MYC plus' where behind 'plus' the specific second oncogene targeted could be mentioned (for example, 'MYC plus BCL2'). Fifty-three of the 177 DH lymphomas (29%) had a diagnosis of BL (44 IG-MYC and 9 non-IG-MYC cases) and 124 (71%) had a diagnosis of another type of B-NHL (76 IG-MYC and 48 non-IG-MYC cases).
Out of the total data set of 973 cases, age and gender were available for 808 (83%) and 932 (96%) cases, respectively, with gender being derived from karyotype information in a small subset of cases. When the cases were divided into five age cohorts (0-15, 16-30, 31-45, 46-60, 61-89 years), the percentage of morphological BL cases with IG-MYC decreased with age, while the percentage of DH BL cases and the other B-NHL cases (both IG-MYC and non-IG-MYC) increased with age. These differences were underscored by the age distributions of the single subgroups (Figure 2 ).
Definition of a core subset of BLFfew cytogenetic differences between children and adults
Out of the 973 cases, 481 cases fulfilled our criteria for the core subset of BL (Figure 1 ; BL IG-MYC single hit): a morphological diagnosis of BL, a cytogenetic detection of an IG-MYC translocation and exclusion of a translocation of BCL2, BCL6 and/or CCND1. The distribution over the different age cohorts was very similar to that of population-based studies with almost half of patients being under the age of 15 years and a strong male preponderance. [36] [37] [38] As pediatric BL is thought to be prototypic for 'true' BL, we further limited the core subset to the 205 pediatric cases (age p15 years). Although even in this group the possibility of a misdiagnosis can not be excluded, the few potentially misdiagnosed cases should not have a strong impact on the overall cytogenetic profile. The mean age of this pediatric subset was 8 years and the majority of patients were male (74%). One hundred eighty-five patients (90%) had a classical t(8;14), 13 patients (6.5%) had a t(8;22) and 7 (3.5%) a t(2;8) variant translocation. In addition to this translocation, few other cytogenetic aberrations were found. Numerical imbalances and additional, non-recurrent translocations (not involving BCL2, BCL6 or CCND1) were detected in 122 and 36 of the 205 cases (60 and 18%, respectively). The most common aberrations ( Figure 3 ) were singular events, with 87% of cases having 0-2 imbalances (0: 40%, 1: 33%, 2: 16% and 42 imbalances: 11%). As a surrogate for genomic complexity, we calculated the complexity score per case in accordance with the publication of the MMML. 25 In short, every non-continuous imbalance per chromosome was counted per case with an additional separation at chromosomal centromeres. Only imbalances were counted, whereas balanced translocations (copy number neutral) had no impact on the complexity score. Although the data cannot be directly compared to the complexity values from the MMML, as different techniques were used, our core BL subset also showed a very low complexity score as published for the molecular BL cases. 25 In addition, this complexity score linearly correlated with the number of aberrant chromosomes or cytobands (Supplementary Figure 1) .
In the adult group (415 years), the mean age was 35 years and again the majority of patients were male (75%). Compared with the pediatric group, more adult cases harbored a variant MYC translocation (22 versus 10%, P ¼ 0.0003). The most common numerical aberrations were almost identical except for a higher prevalence of gain of 8q in the adult group (Figure 3) . Both the average number of imbalances (77% of adults having 0-2 numerical imbalances) and the genomic complexity score (Figure 4b) were very similar for children and adults. This supports recent studies, 25, 26, 39 suggesting that from a cytogenetic and gene expression point of view, BL in children and adults is the same disease. The differences between children and adults found by others in smaller cohorts 36, 40, 41 may represent the inclusion of BL mimickers. In light of these results and also the fact that the genetic profile of the patients with no data on age available were almost identical, we extended our core subset to BL IG-MYC single hit samples independent of patient age (Figure 3 ). The validity of our criteria is also supported by the absence of significant differences in complexity and the proportion of cases diagnosed as BL or another type of B-NHL, when we compared cases published before (N ¼ 280) and after 1994 (N ¼ 201) (Supplementary Figure 2) .
The most common aberrations in this core subset (occurring in 44% of the cases) were copy number gains involving 1q, 7 and 12, and losses involving 6q, 13q32-34 and 17p ( Figure 5 ). To investigate co-occurrence of the different cytogenetic imbalances, we performed cluster analyses on all 696 cases with imbalances (Figure 4c; Supplementary Figure 3) . As a compromise between cross-talk between neighboring intervals and resolution, we used a reduced cluster matrix (86 regions). Figure 4c shows that the core BL clusters together. Focusing on core BL cases (Supplementary Figure 4) , it seemed that gain of 1q is associated with lack of other recurrent abnormalities, with a mostly random scattering of abnormalities in the other cases.
The cytogenetic profile of the BL core subset is different from the cytogenetic profile of other B-NHL cases with a MYC translocation
A MYC translocation is not specific for BL, 12 and is also seen in a subset of morphological DLBCL, [42] [43] [44] follicular lymphoma 45 or mantle cell lymphoma. 46 We found 327 of such cases in our data set, with the majority having a diagnosis of DLBCL (N ¼ 135; 41%), B-cell lymphoma-NOS (N ¼ 79; 24%) and follicular lymphoma (N ¼ 52; 16%) (Supplementary Table 1) . Apart from the DLBCL cases, these cases are commonly thought to represent transformed disease and therefore may harbor a non-IG-MYC breakpoint or additional translocations (for example, involving BCL2 or CCND1), as well as a higher number of numerical aberrations. [47] [48] [49] [50] Indeed, the complexity score was much higher in the other B-NHL cases (Figure 4a ; significance of difference Po0.0001) and gains of 7, 11p, 11q11-22, 12, 18 and X and loss of 4q, 6q13-27, 9, 10p, 15, 17p13 and 17q11-23 were more common compared with the BL core subset ( Figure 5 ). In addition, patients were older (mean 50 versus 23.5 years, Po0.0001; Figure 2 ), and the male/female ratio was lower (Supplementary Table 3 ). These differences persisted when limiting the group to cases with a morphological diagnosis of DLBCL (data not shown).
Morphologic BL without a reported MYC translocation show genetic differences from the core subset
Although in the WHO classification a MYC translocation is a prerequisite for the diagnosis of BL, cases with typical phenotype (morphology and immunohistochemistry) and a very high proliferation index but lacking a MYC translocation often are diagnosed as BL. The precise classification and treatment of these cases is under ongoing discussion. Some authors suggest that such cases should by definition be classified (and treated) as DLBCL, 41 but others claim that such cases behave more aggressively than DLBCL and would benefit from more aggressive therapy. 20 We compared this group (N ¼ 108) with the core subset. The genomic complexity was higher (mean 4.5 versus 1.7 Po0.0001; Figure 4a ). Specifically, gain of 6p, 7p, 11p and 18 and loss of 9, 14q32, 16 and 22 were more common ( Figure 5 ). In addition, this group showed a higher mean age of 29 years (Figure 2 , P ¼ 0.014), and the male/female ratio was lower than that in the core subset (Supplementary Table 2 ). We hypothesize that these 8q24 translocation negative BL cases might represent three subgroups: (a) cases in which the original karyotyping missed a MYC translocation, (b) cases that harbored a different mechanism by which MYC can be overexpressed or (c) cases that were misdiagnosed as BL. In case of (a) or (b), molecular techniques (for example, FISH) could have provided additional information. The most important conclusion could therefore be that this group should prospectively be reduced by applying strict immunohistochemical criteria in combination with proper additional molecular techniques, to detect hidden MYC translocations and to exclude additional breakpoints involving BCL2, BCL6 or CCND1. The final classification (and treatment) of the remaining cases without any indication of a MYC translocation as either BL, DLBCL or a separate entity should be subject of further research.
BL with a non-IG-MYC translocation (BL non-IG-MYC) is a rare entity and is different from the core subset
The activation of MYC by juxtaposition towards one of the IG loci is considered the canonical starting point of BL and therefore a condition sine qua non for the diagnosis. Other mechanisms such as amplification or deregulation by juxtaposition of MYC with other genes might also lead to MYC overexpression and as a result a BL-like morphology. 51, 52 Non-IG-MYC translocation may occur as a secondary event (for example, in follicular lymphoma), resulting in a transformed lymphoma with a BL-like morphology. 53 Although the numbers were small, we compared the genetic profile of the 13 BL with a non-IG-MYC breakpoint with that of the core subset. The genomic complexity of the 13 BL non-IG-MYC cases was much higher (mean 4.6 versus 1.7 P ¼ 0.0003; Figure 4a ) and gain of 7p and 8q22-23 and loss of 8q24, 13q32-34 and X were more common ( Figure 5 ). In addition, the age distribution was skewed towards a higher age ( Figure 2 ) and there was a female preponderance (Supplementary Table 2 ). Our data show that a non-IG-MYC translocation is extremely rare in cases morphologically diagnosed as BL. This corroborates the publication of Bertrand et al. 53 on the largest series (N ¼ 17) of such B-NHL, of which only one case had a BL morphology. These authors suggested that the non-IG-MYC is a secondary event. In line with this conclusion, 9 out of our 13 cases (69%) harbored two translocations involving MYC and also BCL2, BCL6 or CCND1 (to be discussed below). Therefore, we suggest that BL non-IG-MYC cases should not be considered as 'true' BL. For visualization and ordering, the resolution of the genomic status matrix was reduced to 86 intervals (for example, '1q2'), and cases were clustered according to similarity of their imbalance profiles. The color bar on the top represents the assignment of cases to one of the six subgroups. Chromosomal regions run from 1pter (top) to Yqter (bottom), with some regions highlighted due to frequent involvement in BL IG-MYC single hit (and X for guidance). Green: gain; red: loss. cases), 15 at BCL6 (34%) and 5 at CCND1 (11%), 6 cases (14%) having triple hits for MYC, BCL2 and BCL6. As described in the previous paragraph, the IG-MYC translocation in such cases is thought to be the second hit. Various authors have already suggested that such DH BL cases should be considered a separate entity from 'true' BL. 30, 54, 55 When comparing the 44 BL IG-MYC DH cases with the core subset, they appeared to be two separate entities. DH BL patients were much older (mean 51 years, Po0.0001, Figure 2 ), very much similar to the other B-NHL group. Also the genomic complexity of the DH cases was much higher than that in the core subset (mean 5.4 versus 1.7, Po0.0001; Figure 4a ). Gains of 7, 8, 11, 12, 18, 20 and X and loss of 3q27-29, 6q and 15q26
were significantly more common in the DH subgroup ( Figure 5 ). The overlap between BL IG-MYC DH and other B-NHL cases was supported by the fact that DHs were also very frequent in the group of other B-NHL (124/327, 38%). These observations support the available clinical data on this type of lymphoma. The patients have a very aggressive disease that is refractory to current chemotherapeutic treatment. Overall survival is very short, even if treated with high-intensity chemotherapy as used for BL. 56 Another intriguing observation is that a variant MYC translocation towards 2p or 22q occurred more often in DH lymphomas (55%), compared with the core subset (16%). According to Au et al., 57 this supports the hypothesis that the IG-MYC translocation is a secondary event, as one IGH locus is already occupied by the primary translocation (that is, t (11;14) or t(14;18)) and the other IGH allele should remain functional for B-cell receptor signaling. The LLMPP study 25 suggested that at least some DH lymphomas may have a molecular profile that is very similar to that of 'true' BL. A larger series of such lymphomas has to be studied independently from the designed BL predictors to know whether these lymphomas really are similar to 'true' BL or not. For now, there are strong indications that DH BL should be considered a separate disease from 'true' BL. In the new WHO classification of 2008, it is advised that these cases are labeled as a separate group 'B-cell lymphoma with features intermediate between DLBCL and BL'.
Summary and conclusions
In view of the therapeutic and prognostic consequences, the diagnosis of BL should be made with the highest level of certainty. So far this is done with conventional tools, including clinical aspects.
14 With these techniques, the distinction is still hard to make in a subset of cases, especially in the 'gray-zone' between BL and DLBCL, and additional criteria might be of use. In this review, we studied the cytogenetic profile of 'true' BL using the unique, comprehensive collection of cytogenetic data in the 'Mitelman database.' 32 We defined a core subset of BL, that is, lymphomas that were registered as such on a morphological basis, contained an IG-MYC translocation and did not harbor chromosomal translocations of the BCL2, BCL6 or CCND1 loci. As a proof of principle, we compared the cytogenetic profile of this core subset with those of other B-NHL with a MYC breakpoint, with BL cases without a MYC breakpoint, with BL cases with a non-IG-MYC breakpoint and with DH BL cases. The validity of the used criteria for BL was underscored by the absence of any significant increase in the genomic complexity score with age as well as the similarity for cases published before and after the introduction of the REAL classification in 1994. Interestingly, lack of differences in genomic complexity between pediatric and adult cases was independently found by the MMML 39 and LLMPP. 31 We demonstrated that these core BL cases are obviously different from other B-NHL cases with a MYC translocation, as the latter harbor more and also other genetic aberrations than 'true' BL. In 'true' BL gains of 1q, 7 and 12 are found as common recurring events, while (the even less frequent) losses mostly involve 6q, 17p as well as 13q32-q34. Besides differences in cytogenetic complexity and pattern, the available epidemiological data (age and gender distribution) also differed between the two groups. Obviously, morphological criteria remain essential to distinguish BL from other lymphomas. Without availability of gene expression-profiling data, cases with an IG-MYC fusion without evidence of a DH should not be considered as BL, unless indicated by histological appearance. This is supported by our analysis of all 661 IG-MYC single hit lymphoma cases, in which 21% of the 475 cases with a complexity score of 0-2 had an original diagnosis other than BL ( Figure 6 ; Supplementary Figure  5 ). On the other hand, we are aware of the fact that this study cannot give any guideline to definitely identify the rare individual lymphomas that are morphologically different from BL but nevertheless should be considered as molecular BL based on advanced molecular profiling.
Furthermore, we conclude that both DH BL cases as well as the extremely rare BL cases with a non-IG-MYC breakpoint (which in fact mainly represent DH lymphomas) should be separated from 'true' BL, as both their genomic and epidemiological profile are much more similar to other types of B-NHL. This is supported by the MMML data on gene expression and by clinical data showing that such patients have a very aggressive disease that is hardly curable with conventional or high-intensity chemotherapeutic regimens. The awareness on such DH cases is needed especially in older patients, as almost one-third of all cases diagnosed as BL in the database above the age of 60 years appeared to be a DH BL.
There are practical consequences from this review. While lacking the molecular resolution of FISH methods, cytogenetic analysis has the great advantage of giving a 'bird's eye' overview of the many relevant genetic abnormalities in BL, that is, the partner of the MYC locus, the presence or absence of additional translocations and presence or absence and number of other structural abnormalities. Therefore, the authors strongly advise to submit material of any lymphoma suspicious for BL or mimicking diseases for conventional cytogenetic analysis by metaphase karyotyping. In addition, a simple MYC segregation FISH test should be carried out in all cases. More elaborate FISH tests for MYC, IG loci and also BCL2, BCL6 and eventually also CCND1, should be carried out in all BL with some abnormality in morphology or immunohistochemistry for CD5, CD10, BCL2, BCL6 or Ki-67. The use of fewer tests should be strictly restricted to pediatric patients o15 year. Another point to consider is that, although a FISH split signal assay with two probes flanking the MYC gene is the most sensitive and fast assay for detection of MYC breakpoints, it is not able to distinguish IG-MYC from non-IG-MYC fusions and does not cover all MYC breakpoints, that is, far 5 0 and 3 0 breakpoints as well as small insertions are not detected. 58, 59 Furthermore, the steady increase in the age of lymphomas that mimic BL strongly emphasizes that there is no distinct age at which a pathologist can safely make a diagnosis of BL without any ancillary cytogenetic or molecular studies. Morphology versus imbalance complexity in IG-MYC single hit lymphomas. All lymphoma cases with an IG-MYC breakpoint but no 18q21, 3q27 or 11q13 breakpoint were analyzed for imbalance complexity and original histological diagnosis. A histological diagnosis of BL (red/dark grey bars) is associated with a lower complexity and other diagnoses (blue/light grey bars) are gradually increasing in cases with a higher complexity.
